High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.
We evaluated the virological outcome of tenofovir plus didanosine-based regimens in 67 HIV-suppressed patients. After a median follow-up of 26 months (IQR 10.5-40.5), 12 (18%) discontinued the therapy because of virological failure. At virological failure 'de novo' selected mutations were identified in 11 of the 12 failing patients, including the K65R mutation in seven patients. These results argue against the use of tenofovir-didanosine not only in naive patients, but also in previously suppressed patients.
León
Agathe
A
Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Spain.
Mallolas
Josep
J
Martinez
Esteban
E
De Lazzari
Elisa
E
Pumarola
Tomás
T
Larrousse
María
M
Milincovic
Ana
A
Lonca
Montserrat
M
Blanco
Jose Luis
JL
Laguno
Montserrat
M
Biglia
Alejandra
A
Gatell
Josep María
JM
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D016049:Didanosine / Q000627:therapeutic use*; D024921:Drug Resistance, Multiple, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D009154:Mutation; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir; D017211:Treatment Failure
D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine; D016049:Didanosine